This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marwick, T. H. Articles by Schwaiger, M. Search for Related Content PubMed PubMed Citation Articles by Marwick, T. H. Articles by Schwaiger, M. Related Collections Other heart failure Cardiovascular imaging agents/Techniques

Advances in Cardiovascular Imaging

The Future of Cardiovascular Imaging in the Diagnosis and Management of Heart Failure, Part 2

Clinical Applications

Thomas H. Marwick, MD, PhD and Markus Schwaiger, MD, PhD

From the School of Medicine, University of Queensland, Brisbane, Australia (T.H.M.); and Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der lsar, Technische Universität of Munich, Munich, Germany (M.S.).

Correspondence to T. Marwick, University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, Qld 4102, Australia. E-mail t.marwick@uq.edu.au

Received July 29, 2008; accepted July 29, 2008.

Key Words: diagnosis • heart failure • imaging

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Part 1 of these articles focused on the targets of the imaging examination in heart failure (HF) and also reviewed the individual techniques that might be used to address these features.¹ This article will concentrate on specific clinical situations.

	Diagnosis of Early Stage Disease

 
Despite improvements in outcomes related to new treatments for HF, the prognosis of this condition remains poor. The guidelines of the American College of Cardiology and the American Heart Association have emphasized the importance of the detection of early disease in patients at risk (stage A) and those with asymptomatic evidence of left ventricular (LV) damage (stage B).² The identification of these entities should lead to the initiation of prophylactic therapy. In those already on therapy (eg, antihypertensive drugs), the detection of target organ disease (eg, LV hypertrophy) may justify more intensive therapy.

Early Detection of HF
Despite interest in biomarkers, imaging seems to be the optimal strategy for HF screening. It is likely that this will be performed in the community and it is probable (because of cost and availability considerations) that the test of choice will remain echocardiography.³ The increasing workload provided by the HF epidemic may alter the workflow, with an increasing role for imaging in primary care. Although the wider use of echocardiography by noncardiologists will bring challenges with respect to training, this process will be facilitated by progressive miniaturization and automation, which will allow better quantification and reduced subjectivity. The subjective assessment of echocardiography is a well-recognized limitation that has been improved, but not avoided, by modern technical developments. The . . . [Full Text of this Article]

This article has been cited by other articles:

				R. W. Troughton and A. M. Richards B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 216 - 225. [Abstract] [Full Text] [PDF]